Abstract
We have demonstrated antitumor activity against refractory human glioma and pancreatic tumors with 6-methylpurine (MeP) using either a suicide gene therapy strategy to selectively release 6-methylpurine in tumor cells or direct intratumoral injection of 6-methylpurine itself. A single i.p. injection in mice of the prodrug 9-β-d-[2-deoxyribofuranosyl]-6-methylpurine (MeP-dR; 134 mg/kg) caused sustained regression lasting over 70 days of D54 (human glioma) tumors transduced with the Escherichia coli purine nucleoside phosphorylase (PNP), and a single intratumoral injection of 6-methylpurine (5–10 mg/kg) elicited prolonged delays of the growth of D54 tumors and CFPAC human pancreatic carcinoma. Because the D54 tumor doubling time is >15 days, the experiments indicate that prodrug activation by E.coli PNP engenders destruction of both dividing and nondividing tumor compartments in vivo and, therefore, address a fundamental barrier that has limited the development of suicide gene strategies in the past. A prolonged retention time of 6-methylpurine metabolites in tumors was noted in vivo (T1/2 >24 h compared with a serum half-life of <1 h). By high-pressure liquid chromatography, metabolites of [3H]MeP-dR were 5- to 6-fold higher in tumors expressing E. coli PNP. These experiments point to new endpoints for monitoring E.coli PNP suicide gene therapy, including intratumoral enzymatic activity, in situ (intratumoral) prodrug conversion, and tumor regressions after direct injection of a suicide gene toxin. The findings also help explain the strong in vivo bystander killing mechanism ascribed by several laboratories to E.coli PNP in the past.
Footnotes
-
These studies were supported by 5 U19 CA67763-05 and P30 DK54781. The technology described in this article has been licensed to PNP Therapeutics (Birmingham, AL); however, the company has provided no financial support to the studies described above.
-
DOI: 10.1124/jpet.102.044743
- Abbreviations:
- HSV-tk
- herpes simplex virus thymidine kinase
- PNP
- purine nucleoside phosphorylase
- MeP
- 6-methylpurine
- MeP-dR
- 9-β-d-[2-deoxyribofuranosyl]-6-methylpurine
- HPLC
- high-performance liquid chromatography
- i.t.
- intratumorally
- Received September 24, 2002.
- Accepted December 4, 2002.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|